In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.
Neratinib in combination with capecitabine induced a 34% reduction in the risk of disease progression or death as treatment of patients with HER2-positive breast cancer who had central nervous system metastases at baseline compared with lapatinib and capecitabine.
In the phase 3 PROTECTIVE-2 trial, patient with breast cancer who received plinabulin and pegfilgrastim experienced a reduction in the incidence of profound neutropenia that was 53% more effective than that of chemotherapy, according to findings presented during the 2020 San Antonio Breast Cancer Symposium.
The GP2 immunotherapy in combination with granulocyte-macrophage colony-stimulating factor induced a 100% disease-free survival with potent responses as treatment of patients with HER2/neu 3–positive disease who received adjuvant trastuzumab .
Treatment with amcenestrant demonstrated antitumor activity in postmenopausal women with heavily pretreated advanced or metastatic estrogen receptor–positive breast cancer.
Patients with HER2-positive metastatic breast cancer treated with fam-trastuzumab deruxtecan-nxki had continued to experience extended durable responses and overall survival rates, along with tolerable toxicity in the phase 2 DESTINY-Breast01 study for which data were presented during the 2020 San Antonio Breast Cancer Symposium.
In the phase 3 KX-ORAX-001 clinical trial, treatment with paclitaxel in combination with encequidar achieved a 26.5% reduction in the risk of death compared with paclitaxel by intravenous injection in patients with metastatic breast cancer.
Invasive disease-free survival was prolonged in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer treated with abemaciclib in combination with standard endocrine therapy in the phase 3 monarchE trial, according to a presentation at the 2020 San Antonio Breast Cancer Symposium.
A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.
A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration leads to high, durable, and consistent responses in patients with follicular lymphoma across multiple subgroups. Data from the study were presented during the virtual 2020 American Society of Hematology Annual Meeting.
Treatment with asciminib led to an almost doubling of the major molecular response rate compared with bosutinib at 24 weeks in patients with chronic-phase chronic myeloid leukemia.
A 20-mg 3-times-weekly or twice-weekly dosing schedule of panobinostat combined with subcutaneous bortezomib plus dexamethasone induced durable responses as treatment of patients with relapsed or refractory multiple myeloma and demonstrated an acceptable safety profile in the phase 2 PANORAMA 3 study.
Promising antitumor activity, as well as an acceptable safety profile, continues to be demonstrated with odronextamab, a novel CD20xCD3 bispecific antibody, as treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Early signs of clinical activity were observed in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia who were treated with an investigational allogeneic off-the-shelf CD22-directed therapy.
Treatment with axicabtagene ciloleucel resulted in high rates of durable responses in patients with indolent non-Hodgkin lymphoma.
A post-hoc analysis of the SADAL trial showed there was clinical benefit with selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma regardless of age.
Results of the CLARINET FORTE study indicate that a dosing strategy of lanreotide given every 14 days may be a viable and safe option when the standard administration of every 28 days is not acceptable.
During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.
During a virtual presentation for the 38th Annual Chemotherapy Foundation Symposium, Janice M. Mehnert, MD explained the science behind selecting the optimal adjuvant therapy for patients with BRAF-mutant melanoma. The options Mehnert weighed were immunotherapy and BRAF-targeted therapy.
In the phase 2 single-arm innovaTV 204 trial, treatment with tisotumab vedotin led to an objective response rate (ORR) of 24% (95% CI, 15.9%-33.3%) in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab (Avastin). The encouraging result was announced during a presentation at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress.
A primary analysis from the phase 3 IPATential150 trial demonstrated the benefit of the addition of ipatasertib to abiraterone acetate and prednisone in the treatment of patients with metastatic castration-resistant prostate cancer with PTEN loss, according to results presented at the 2020 ESMO Virtual Congress.
In preclinical models of triple-mutated EGFR-positive non–small cell lung cancer, the investigational agent, BLU-945 induced robust antitumor responses, according to results presented at the 2020 European Society of Medical Oncology Virtual Congress.
According to results from the phase 3 CROWN trial, the third-generation ALK tyrosine kinase inhibitor loralitinib achieved a significant improvement in progression-free survival as well as higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.
In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status, plus a tolerable safety profile, according to data from 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress.
Frontline nivolumab in combination with cabozantinib demonstrated a 49% reduction in the risk of disease progression or death as treatment of patients with advanced renal cell carcinoma.
Avelumab in combination with best supportive care as frontline maintenance in patients with advanced or metastatic urothelial carcinoma who had not progressed on first-line platinum-based chemotherapy led to improvements in both progression-free and overall survival.
In a phase 2 clinical trial, promising clinical activity was observed with cemiplimab in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors, regardless of PD-L1 expression, according to findings presented at the 2020 ESMO Virtual Congress.